Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005606 · ClinicalTrials.gov registry record · Phase 2
Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005606: Completed Phase 2 study, sponsored by Northwestern University.
NCT00005606 is a Phase 2 study that has completed, run by Northwestern University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005606, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Peripheral blood lymphocyte therapy may be effective in the treatment and prevention of Epstein-Barr virus infection following transplantation. PURPOSE: Phase II trial to study the effectiveness of peripheral blood lymphocyte therapy in treating and preventing lymphoproliferative disorders in patients who have Epstein-Barr virus infection following transplantation.
Interventions
- BIOLOGICAL allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
- BIOLOGICAL autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-02 |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
What the finished NCT00005606 record still lists
NCT00005606 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes is the first listed.
NCT00005606 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005606 about?
NCT00005606 is a clinical study titled "Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation". RATIONALE: Peripheral blood lymphocyte therapy may be effective in the treatment and prevention of Epstein-Barr virus infection following transplantation. PURPOSE: Phase II trial to study the effectiveness of peripheral blood lymphocyte therapy in treating and preventing lymphoproliferative disorde...
What is the current status of trial NCT00005606?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-02. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00005606?
The interventions under investigation include: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes (BIOLOGICAL), autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005606?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia